Imperial Oil Limited Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Relay Therapeutics Inc. Common Stock trades at $17.07 (market cap $3.81B). The key difference: Imperial Oil Limited Common Stock is far larger — about 16.3× Relay Therapeutics Inc. Common Stock's market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IMO | RLAY | |
|---|---|---|
Market Cap | $62.22B | $3.81B |
Volume | 560,544 | 1,706,150 |
Sector | Energy | Health |
52-Week High | $138.33 | $20.75 |
52-Week Low | $83.72 | $6.05 |
Enterprise Value | $63.13B | $2.93B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 5 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
Trailing returns across standard periods
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →